Marcio Souza; President, Chief Executive Officer, Director; Praxis Precision Medicines Inc Tim Kelly; Chief Financial Officer; Praxis Precision Medicines Inc Good day and thank you for standing by.

Praxis recognized $0.3 million in collaboration revenue during the three months ended September 30, 2024, compared to $0.5 ...

Praxis Precision Medicines is advancing its CNS disorder therapies, with promising developments in its late-stage drugs: relutrigine for developmental and epileptic encephalopathies, ulixacaltamide ...

John Goekler’s hands started shaking 30 years ago and it progressed to the point where he couldn’t write a legible check, hold a can of soda or easily put toothpaste on his toothbrush. Goekler, 75, ...

The symptoms typically begin in early adulthood and become progressively more severe as one ages. What may begin as a feeling of trembling within the body can eventually become a ...

Two years after Idorsia and Neurocrine’s calcium channel blocker flunked a pair of phase 2 studies in quick succession, the biotechs have finally decided to part ways. | Two years after Idorsia and ...